Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CVX-045 · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CVX-045 | BIOLOGICAL | Weekly, intravenous dose |
Inclusion Criteria: * Confirmed advanced solid tumors unresponsive to currently available therapies, or for which there is no standard therapy. * Adequate coagulation, liver and renal function. * Candidate for DCE-MRI evaluation. * ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
CVX-045 is an investigational monoclonal antibody being developed for the treatment of advanced solid tumors. It is intended for patients with various types of cancer, including neoplasms, carcinoma, and malignancy. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
CVX-045 is a monoclonal antibody, but its specific molecular target has not been disclosed. The drug is being studied for its safety and pharmacokinetics in patients with advanced solid tumors. As a monoclonal antibody, it is designed to bind to a specific protein, but the exact target is not publicly available.
CVX-045 is being developed by Pfizer, Inc., a multinational pharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. Pfizer is conducting clinical research to evaluate the safety and pharmacokinetics of CVX-045 in patients with advanced solid tumors.
CVX-045 is in Phase 1 clinical development. It is an investigational drug and has not received regulatory approval. The Phase 1 trial, which has been completed, was designed to assess the safety and pharmacokinetics of CVX-045 in patients with advanced solid tumors.
CVX-045 has one completed Phase 1 clinical trial with the identifier NCT00879554. The study, titled 'A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors,' enrolled 40 participants in the United States. It was an uncontrolled, non-randomized trial that did not use a placebo or double-blind design.
CVX-045 is a unique investigational monoclonal antibody and no alternative names have been reported. It is being developed by Pfizer for advanced solid tumors. Patients and healthcare providers should refer to the drug by its designated name, CVX-045, in clinical and research contexts.